(FDA) in 2006, manufacturers were required to initiate large postapproval studies to evaluate the performance and safety of these devices over a 10-year period. 8 The Breast Implant Follow-up Study (BIFS-001) is a large, 10-year study designed to address this FDA requirement in women receiving Natrelle (Allergan plc, Dublin, Ireland) round silicone breast implants. Natrelle silicone implants are available worldwide for primary augmentation, revision-augmentation, primary reconstruction, and revision-reconstruction, and have demonstrated long-term safety and patient satisfaction in clinical trials. [9] [10] [11] In addition to collecting long-term safety data, 12 BIFS-001 evaluated lactation outcomes in women who experienced live births after undergoing primary augmentation with Natrelle round silicone implants or saline implants. The present analysis compares lactation outcomes in women who had surpassed the 5-year visit window, both overall and stratified by incision site, implant location, implant size, and subject age.
METHODS

Study Design
BIFS-001 is an ongoing, multicenter, 10-year observational study in women who received Natrelle round silicone or saline implants. Patient enrollment began in February 2007 and all patients were enrolled by March of 2010. All silicone implants were required to be Natrelle devices. The study was approved by the institutional review board (IRB) at each investigational site and a central IRB (IRB Company Inc, Buena Park, CA) and is being conducted in accordance with Good Clinical Practice guidelines and World Health Organization guidelines. The study is registered at clinicaltrials.gov (NCT00443274). All patients provided written informed consent before undergoing any study-related procedure.
Patients
Inclusion and exclusion criteria for BIFS-001 have been published previously. 12, 13 This subanalysis of BIFS-001 included only women who experienced live births after undergoing primary augmentation surgery with unilateral or bilateral silicone implants or saline implants. Eligible patients were women aged 22 years or older who were fluent in English or Spanish. Patients were excluded if they were transgender or were deemed by the investigator to be unsuitable candidates for long-term follow-up. The incision site and implant location were selected at the discretion of the investigator.
Assessments
Patients completed questionnaires at baseline and annually after surgery, which included a series of questions regarding pregnancy and lactation as well as other outcomes (eg, adverse events and satisfaction) that are reported separately. 12, 14 Mothers who had stopped breast-feeding a baby that was born after their primary augmentation procedure were asked if they had any of the following complications before they stopped breast-feeding: mastitis, not enough milk production, too much milk production, excess pain, nipple inversion, or another problem with their breasts.
Statistical Analyses
Lactation outcomes for women who had surpassed the 5-year visit window were compared for patients with silicone and saline implants by means of summary statistics and odds ratios (silicone/saline) with 90% confidence intervals (OR [90% CI]). Adjusted ORs were estimated from a logistic regression model and adjusted for covariates of breast-feeding difficulty history, body mass index (BMI), incision site, miscarriage history, current alcohol consumption, race, smoking status, and education level. Rates of breast-feeding and lactation complications were stratified by incision site for implant placement (inframammary, periareolar, mastopexy, and transaxillary), implant location (partial submuscular, complete submuscular, and subglandular), implant size (<400 cc vs ≥400 cc), and mother's age at the time of implantation (22-29 years vs ≥30 years).
RESULTS
Patients
The study enrolled 29,148 eligible women who underwent primary augmentation with silicone implants and 13,725 eligible women who underwent primary augmentation with saline implants. Of 4679 women who gave birth at least once after they underwent primary augmentation, 3715 (79.4%) reported breast-feeding at least one baby during the study. Table 1 shows the baseline demographics and baseline pregnancy and breast-feeding history for women who breast-fed during the study. The median (range) age at enrollment for the women who breast-fed was 27.0 years (range, 22-44 years) in the silicone group and 26.5 years (range, 22-42 years) in the saline group. In both groups, the majority were white (silicone, 76.6%; saline, 68.0%) and had normal BMI (18.5-24.9 kg/m 2 ) at baseline (silicone, 80.4%; saline, 79.0%). Compared with the primary augmentation population in the overall study in both the silicone and saline groups, the women in the current study were younger (median, 27 years vs 32-34 years) and had a smaller proportion of individuals with BMI ≥25 kg/m 2 (9-12% vs 14-19%). 13 The median duration of follow-up after breast augmentation to the last date of data collection was 3.6 years (range, 0.85-8.3 years) for the silicone group and 3.8 years (range, 0.88-8.5 years) for the saline group.
Approximately 60% of the women who breast-fed during the study had been pregnant before they underwent augmentation ( Table 1 ). The proportion of those women who had a prestudy history of trying to breast-feed was higher in the silicone group (52.8%) than in the saline group (28.4%). Among women who breast-fed before augmentation, the most commonly (>10%) reported prestudy breast-feeding complications were insufficient milk production (silicone, 13.5%; saline, 14.1%) and mastitis (silicone, 13.3%; saline, 11.4%).
Lactation Outcomes After Primary Augmentation
Of the 5736 live births during the study (silicone, 3695 births; saline, 2041 births), 80.0% and 75.9% of babies were breast-fed by women in the silicone group and saline group, respectively (Table 2 ). Most women who did not breast-feed chose not to for reasons other than their implants or due to a problem with the baby that prevented breast-feeding. In approximately 4% of births, the baby had a problem that prevented breast-feeding. Breast-feeding rates were comparable among babies of mothers with different incision sites, implant sizes, and age categories ( Table 2 ). The proportion of infants who were breast-fed was slightly lower for mothers with subglandular implant placement (silicone, 74.8%; saline, 67.7%) compared with submuscular placement (partial submuscular: silicone, 81.3%; saline: 76.1%; complete submuscular: silicone, 79.3%; saline, 76.6%). Overall, most infants (94.4%) were able to suckle (ie, able to obtain nourishment from either a bottle or the breast).
The percentages of mothers reporting lactation complications were similar in the silicone and saline implant groups and for both mothers who had single vs multiple births during the study (Table 3 ). The most common complication was insufficient milk production, which was reported for 19.6% and 19.8% of single births in the silicone and saline groups, respectively, corresponding to 25.0% and 26.3% of breast-fed single births. Mastitis was reported for 4.1% and 3.7% of single births in the silicone and the saline groups, respectively, or 5.2% and 4.9% of breast-fed single births. The complications of excess pain, excessive milk production, and nipple inversion were all reported for fewer than 5% of single births. The only complication that was significantly different between the silicone and saline groups was excessive milk production, (Figure 1 ), for partial submuscular or complete submuscular pocket locations (Figure 2) , and for smaller (<400 cc) or larger implants (≥400 cc) (Figure 3 ). Insufficient milk production was reported more frequently among women with silicone implants placed via mastopexy incision (26.2%) compared with inframammary (18.8%), periareolar (19.6%), and transaxillary incisions (16.1%); rates of insufficient milk production with saline implants were highest with mastopexy (29.2%) and transaxillary incisions (23.7%) compared with inframammary (18.2%) and periareolar incisions (20.2%; Figure 1 ). In general, complication rates were slightly higher among women with subglandular implant placement compared with submuscular implants (Figure 2 ). The rate of insufficient milk production was 25.1% with subglandular implant placement, 19.5% with partial submuscular placement, and 17.9% with complete submuscular placement for silicone implants; rates for saline implants followed a similar pattern (Figure 2 ). It should be noted that for the saline group the sample size for subglandular implant placement was relatively small (n = 42) compared with partial submuscular (n = 747) and complete submuscular (n = 534) implant placement. Younger (22-29 years) and older mothers (≥30 years) experienced lactation complications at similar rates (Figure 4) .
Representative photographs show 2 women before augmentation, with silicone implants before or during pregnancy, during lactation, and after stopping breast-feeding (Supplemental Figures 1 and 2 , available online at www. aestheticsurgeryjournal.com).
DISCUSSION
BIFS-001 is the first study to report lactation outcomes in a large population of women who breast-fed after they underwent primary breast augmentation with Natrelle round silicone implants or saline implants. The study population included more than 3500 women, who gave birth to more than 5000 babies. Data from women who surpassed the 5-year visit window demonstrate that mothers with implants decided to breast-feed in approximately 80% of births, a rate that aligns well with the rate of breast-feeding initiation in the general population in the United States (79% of newborns in 2011), 15 as well as previously reported rates of breast-feeding among mothers with augmented breasts (63%-93%). 4, 16, 17 The incidences of complications in BIFS-001 were generally similar among women with silicone and saline implants, regardless of incision site, implant location, implant size, and subject age. The most common lactation complication reported in the current study was insufficient milk production, which occurred at a rate (18%-20%) that was not unexpected based on other studies of breast-feeding mothers with and without implants. The Infant Feeding Practice Study II (IFPS II), a longitudinal survey of approximately 5000 pregnant women in the United States, evaluated breast-feeding outcomes in 2586 breast-feeding mothers of single birth infants born between 2005 and 2006. 18 Although the presence of breast implants was not assessed in IFPS II, it can be assumed that most of these women were implant naïve. Nearly half (47%) of mothers stopped breast-feeding their infants before they reached the age of 3 months, and approximately half of those mothers cited insufficient milk supply as a reason for stopping breast-feeding. Inadequate milk production was reported by 36 (11%) women who breast-fed in a study that evaluated lactation outcomes in 323 women who attempted breast-feeding after primary augmentation with Natrelle 410 form-stable implants. 19 The perception that a mother is not producing enough milk for adequate growth of her infant is common among women who breast-feed, but it may not be accurate. 18, 20 A study of 45 exclusively breast-fed infants demonstrated that despite energy intake lower than formula-fed infants, there was Percentage of patients with lactation complications shown by incision site in women who had single-births after they underwent primary augmentation with silicone or saline implants. Data for the complications of nipple inversion and excessive milk production are not shown, because they occurred in fewer than 2.5% of patients in any group.
no difference in rate of weight gain. 20 Data regarding the duration of breast-feeding, infant weight gain, or the need for formula supplementation are not available for BIFS-001; therefore, a more thorough evaluation of sufficiency of milk production after breast augmentation in this population is not possible. Three studies published in the 1990s reported that periareolar incisions were associated with higher rates of lactation problems, such as insufficient milk production or nipple pain, compared with inframammary incisions, [5] [6] [7] although this has not been confirmed in more recent studies. 4, 19 One author proposed that the problems in women with periareolar incisions were related to degree of disruption of glandular tissue with periareolar incision rather than the site of skin incision. 21 We did not observe a higher incidence of lactation problems with periareolar incision in BIFS-001. However, mastopexy was associated with higher rates of insufficient milk production than other incision sites, presumably due to the technical aspects of this surgery. Percentage of patients with lactation complications shown by implant size group (<400 cc vs ≥400 cc) in women who had single-births after undergoing primary augmentation with silicone or saline implants. Data for the complications of nipple inversion and excessive milk production are not shown, because they occurred in fewer than 2.5% of patients in any group.
Complication rates were slightly higher in patients with subglandular implant placement compared with submuscular placement, suggesting greater disruption of glandular tissue with this technique. Although it is not known whether subglandular placement is associated with greater pressure on glandular tissue compared with submuscular placement, it is possible that the implant itself applies pressure to the glandular tissue, which could, in turn, inhibit the ability to produce milk. 5, 21, 22 One might expect that pressure applied to the glandular tissue by the implant could result in impaired drainage from the milk ducts, 22 potentially increasing the risk of mastitis in women with implants. 23 However, our data suggest that mastitis may have occurred at a higher rate before augmentation than after augmentation in BIFS-001. Approximately 11% to 13% of women in this analysis who had breast-fed before undergoing breast augmentation had a prestudy history of mastitis. In contrast, mastitis was reported for approximately 5% of breast-fed single births after augmentation. The rate was slightly higher among women who had subglandular (6.2%) vs partial or complete submuscular (3%-4%) placement of silicone implants. Although the preaugmentation incidence of mastitis aligns with reported rates in the general population, the postaugmentation rate was lower than in the general population. Approximately 20% (70/346) of implantnaïve mothers developed mastitis while breast-feeding in one prospective cohort study conducted at 2 hospitals in Australia between 2009 and 2011. 24 The incidence of mastitis was 9.5% in a US study (n = 840) by physician diagnosis in the initial 12 weeks of breast-feeding. 25 The reason for the low rate of mastitis in women with implants in the current study is unclear.
Breast and nipple pain are common concerns for all nursing women and have been shown to contribute to early discontinuation of breast-feeding. 18, 26 The IFPS II found that approximately 75% of mothers (n = 2561) reported experiencing pain at some point during the first 2 weeks of nursing. 27 Of those who reported pain while breast-feeding, 5.4% rated the pain as 10 on a scale of 0 (no pain) to 10 (worst possible pain) during the first week and 3.4% rated the pain as 10 in the second week of breast-feeding. Although the threshold for "excessive pain" was not defined in the questionnaire used in BIFS-001, the reported incidence of excessive pain (~5%) is consistent with reports for the general population.
The complication of excessive milk production was reported at a significantly lower rate in the silicone group (0.6% of single births) than in the saline group (1.3% of single births). Further study is needed to determine if this difference is clinically meaningful, given the relatively low number of reported events (<1.5% or <20 events in any group).
Several limitations of the current analysis should be noted. The results of this study are limited to Allergan breast implants. While both smooth and textured round implants were included in the study, textured devices accounted for only 8.8% of silicone and 2.9% of saline implants. 12 This imbalance did not allow for meaningful comparisons between textured and smooth devices. Mother-reported complications of insufficient milk production may be subjective and variable. However, standardized objective measures of milk production are not available. Furthermore, retrospective surveys are limited by the possibility that subjects' recall of past events may not be accurate. Complications with breast-feeding prior Figure 4 . Percentage of patients with lactation complications shown by age group (22-29 years vs ≥30 years) in women who had single births after they underwent primary augmentation with silicone or saline implants. Data for the complications of nipple inversion and excessive milk production are not shown, because they occurred in fewer than 2.5% of patients in any group. to breast augmentation were based on recall of events that may have occurred many years in the past. Complications reported after breast augmentation were based on subject's recall after they had completed breast-feeding. It is therefore possible that some complications may be underreported.
CONCLUSIONS
In this large group of women who underwent primary breast augmentation, most were able to successfully breast-feed their infants without complications. Lactation complications were similar between the silicone and saline groups regardless of incision type, implant placement, implant size, or age. The incidence of lactation complications was comparable to reports of such complications in the general population of women who elect to breast-feed. These findings from BIFS-001 indicate a positive outlook for the ability of women to breast-feed after primary breast augmentation.
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